Johnson & Johnson: Q3 Earnings Insights

Shares of Johnson & Johnson JNJ decreased 1.2% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share rose 3.77% year over year to $2.20, which beat the estimate of $1.98.

Revenue of $21,082,000,000 rose by 1.70% from the same period last year, which beat the estimate of $20,200,000,000.

Looking Ahead

The upcoming fiscal year's EPS expected to be between $7.95 and $8.05.

The upcoming fiscal year's revenue expected to be between $81,200,000,000 and $82,000,000,000.

Conference Call Details

Date: Oct 13, 2020

Time: 08:30 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/k7ozm2yc

Recent Stock Performance

52-week high: $157.00

Company's 52-week low was at $109.16

Price action over last quarter: Up 0.37%

Company Profile

Johnson & Johnson is the world's largest and most diverse healthcare firm. Three divisions make up the firm: pharmaceutical, medical devices and diagnostics, and consumer. The drug and device groups represent close to 80% of sales and drive the majority of cash flows for the firm. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. The device segment focuses on orthopedics, surgery tools, vision care, and a few smaller areas. The last segment of consumer focuses on baby care, beauty, oral care, over-the-counter drugs, and women's health. Geographically, just over half of total revenue is generated in the United States.